Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

RSV

- PMLiVE

Moderna’s RSV vaccine mRESVIA granted FDA approval for use in older adults

The approval marks the first time an mRNA vaccine has been approved for a disease other than COVID-19

- PMLiVE

Bristol Myers Squibb’s Breyanzi receives FDA approval for mantle cell lymphoma

The rare form of non-Hodgkin lymphoma accounts for around 3% of all NHL cases

- PMLiVE

Merck KGaA signs definitive agreement to acquire Mirus Bio in deal worth $600m

The deal aims to advance Merck’s viral vector manufacturing of cell and gene therapies

- PMLiVE

Pfizer’s RSV vaccine Abrysvo shown to maintain strong efficacy in older adults

RSV infections account for up to 160,000 hospitalisations among older adults each year in the US

- PMLiVE

First UK cancer patients receive Moderna’s experimental mRNA therapy

The Mobilize trial is evaluating mRNA-4359 in cancers including melanoma and lung cancer

- PMLiVE

AstraZeneca/Sanofi’s RSV treatment shown to reduce hospitalisations in infants

Beyfortus showed an over 80% reduction in hospitalisations associated with the virus

- PMLiVE

AstraZeneca to acquire vaccine developer Icosavax in deal worth up to $1.1bn

The transaction includes a vaccine candidate targeting two causes of severe respiratory infection

- PMLiVE

Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults

RSV is associated with 15,000 hospital admissions in infants under six months every year in England

- PMLiVE

Moderna and CEPI enter pandemic preparedness partnership

The partnership aims to expand infectious disease targets for mRNA vaccine technology

- PMLiVE

The Power of Disease Awareness in Infectious Disease Education at IDWeek 2023

Medscape Education had one of its biggest conferences of the year with IDWeek 2023, hosting six educational symposia and presenting five scientific posters highlighting the outcomes of recent infectious disease...

Medscape Education Global

- PMLiVE

WHO publishes new infodemic management tools for pandemic preparedness

The taxonomy will support pandemic planning for respiratory pathogen disease events

- PMLiVE

GSK’s RSV vaccine Arexvy shows promise in adults aged 50 to 59 years

Arexvy has already been approved in the US and Europe to protect those aged 60 years and older

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links